T1	hpi_start 0 11	Subjective:
T2	SectionSkip 5675 7139	FINDINGS:  Visualized lung bases:  Please see separately dictated report from same day for chest findings.   Liver:    Interval development of periportal edema involving the lateral segment 
 of the left hepatic lobe with associated mild biliary dilatation. This may be postsurgical in nature. However, tumor infiltration is not entirely excluded. Attention on follow-up.  Small pneumobilia in the left lobe is noted. Patient is status post hepaticojejunostomy.  Interval increase in size of a 14 mm hypodense lesion in segment March 14 (previously 9 mm). New 5 mm hypodense lesion in segment 8/4A is noted and is suspicious for metastatic disease. Other hypodense liver lesions are not significantly changed.  Gallbladder:  Surgically absent.   Spleen:  Unremarkable  Pancreas:  Patient is status post Whipple procedure . There is moderate dilatation of the main pancreatic duct, stable to slightly increased from prior exam.  Adrenal Glands:  Unremarkable  Kidneys:  Unremarkable  Vasculature:  Unremarkable  GI Tract:  Status post Whipple procedure. Otherwise, unremarkable.  Pelvis:  Enhancing mass in the endometrial canal is noted. This may be secondary to an intracavitary fibroid. However, recommend pelvic ultrasound to exclude malignancy.  Lymphadenopathy: Multiple reactive mesenteric lymph nodes are noted.  Ascites: Small ascites. There is small amount of fluid and stranding around the central mesentery.  Bones:  No suspicious lesions     04/26/2015
T3	SectionAnnotate 7142 7153	IMPRESSION:
T4	SectionSkip 9225 10170	FINDINGS:  Bilateral nonspecific thyroid nodules again noted, including an 8 mm hypodense nodule in the right thyroid lobe.  Scattered lower lobe subsegmental atelectasis is new from previous. No consolidation or pleural effusion. Unchanged calcified granuloma in the right upper lobe. Few scattered pulmonary nodules measuring up to 3 mm in the subpleural aspect of the right upper lobe are unchanged, series 301 image 58.  No lymphadenopathy. Scattered calcified mediastinal and hilar lymph nodes are unchanged and suggestive of old 
 granulomatous disease.  The heart and great vessels show no significant abnormality. Right chest wall Port-A-Cath tip extends through the tricuspid valve into the right ventricle, previously terminating in the right atrium.  No suspicious bone lesions are identified. Mild degenerative changes of the thoracic spine.  Please see a separately reported examination for evaluation of the abdomen.     04/26/2015
T5	SectionAnnotate 10362 10373	Assessment:
T6	PROBLEM 158 178	abdominal discomfort
T7	PROBLEM 180 188	bloating
T8	PROBLEM 193 212	eventually jaundice
T9	TREATMENT 215 228	A metal stent
T10	TEST 304 311	CT scan
T11	PROBLEM 334 368	a mass in the head of the pancreas
T12	PROBLEM 373 392	a 2 cm adrenal mass
T13	TEST 395 412	A followup PET/CT
T14	PROBLEM 441 465	the mass in the pancreas
T15	TEST 481 508	An ultrasound of the pelvis
T16	PROBLEM 531 575	a 3.2 cm fibroid in the fundus of the uterus
T17	PROBLEM 580 601	thickened endometrium
T18	PROBLEM 607 621	adnexal masses
T19	TEST 633 636	EUS
T20	PROBLEM 662 694	encasement of the hepatic artery
T21	PROBLEM 699 728	invasion into the portal vein
T22	TEST 731 750	FNA of the pancreas
T23	PROBLEM 760 774	adenocarcinoma
T24	TEST 816 845	her pancreas protocol CT scan
T25	PROBLEM 890 915	peritoneal carcinomatosis
T26	TEST 932 945	a laparoscopy
T27	PROBLEM 981 1027	a small amount of ascites in the pelvic region
T28	TEST 1032 1040	washings
T29	PROBLEM 1057 1084	A small lesion in the liver
T30	PROBLEM 1129 1135	a cyst
T31	TEST 1146 1161	her laparoscopy
T32	PROBLEM 1177 1197	pleuritic chest pain
T33	PROBLEM 1202 1226	some shortness of breath
T35	TEST 1282 1289	CT scan
T36	PROBLEM 1338 1373	some interlobular septal thickening
T37	PROBLEM 1378 1402	a ground glass opacities
T38	TREATMENT 1430 1439	treatment
T39	TREATMENT 1445 1464	modified FOLFIRINOX
T40	TREATMENT 1534 1552	surgical resection
T41	TREATMENT 1581 1590	a pylorus
T42	TREATMENT 1591 1616	preserving pancreatectomy
T43	TREATMENT 1622 1642	open cholecystectomy
T44	TREATMENT 1647 1658	portal vein
T45	TREATMENT 1663 1687	hepatic artery resection
T46	TREATMENT 1692 1711	interposition graft
T47	TEST 1713 1731	Surgical pathology
T48	PROBLEM 1741 1769	a 1.7 cm residual tumor mass
T49	PROBLEM 1801 1812	tumor cells
T50	TEST 1824 1831	Margins
T51	PROBLEM 1861 1881	positive lymph nodes
T52	PROBLEM 1914 1938	unexpected complications
T53	TREATMENT 1991 2002	her surgery
T54	PROBLEM 2023 2053	continued abdominal discomfort
T55	TREATMENT 2182 2193	her surgery
T56	TEST 2220 2222	BP
T57	TEST 2232 2237	Pulse
T58	TEST 2243 2247	Temp
T59	TEST 2248 2251	Src
T60	TEST 2258 2259	C
T61	TEST 2278 2282	Resp
T62	TEST 2288 2290	Ht
T63	TEST 2311 2313	Wt
T64	TEST 2342 2345	BMI
T65	TEST 2360 2364	SpO2
T66	TEST 2372 2375	LMP
T67	PROBLEM 2436 2450	icterus  Nodes
T68	PROBLEM 2454 2473	clinical adenopathy
T69	PROBLEM 2488 2499	thyromegaly
T70	PROBLEM 2542 2548	murmur
T71	PROBLEM 2552 2558	gallop
T72	PROBLEM 2560 2582	Abd somewhat distended
T73	PROBLEM 2598 2604	tender
T74	TEST 2608 2617	palpation
T75	PROBLEM 2622 2632	fluid wave
T76	PROBLEM 2661 2665	rash
T77	PROBLEM 2669 2678	petechiae
T78	PROBLEM 2695 2700	edema
T79	TEST 2705 2717	pedal pulses
T80	PROBLEM 2742 2761	gross focal deficit
T81	TEST 2814 2834	COMPLETE BLOOD COUNT
T82	TEST 2873 2878	Value
T83	TEST 2879 2882	Ref
T84	TEST 2883 2888	Range
T85	TEST 2892 2895	WBC
T86	TEST 2896 2901	Count
T87	TEST 2922 2936	L    RBC Count
T88	TEST 2943 2949	*****)
T89	TEST 2972 2982	Hemoglobin
T90	TEST 3015 3025	Hematocrit
T91	TEST 3052 3055	MCV
T92	TEST 3075 3078	MCH
T93	TEST 3093 3095	pg
T94	TEST 3099 3103	MCHC
T95	TEST 3118 3122	g/dL
T96	TEST 3126 3140	Platelet Count
T97	TEST 3156 3161	x10E9
T98	TEST 3167 3177	Neutrophil
T99	TEST 3178 3186	Absolute
T100	TEST 3187 3192	Count
T101	TEST 3209 3214	x10E9
T102	TEST 3220 3230	Lymphocyte
T103	TEST 3231 3234	Abs
T104	TEST 3235 3238	Cnt
T105	TEST 3255 3260	x10E9
T106	TEST 3266 3278	Monocyte Abs
T107	TEST 3279 3284	Count
T108	TEST 3301 3306	x10E9
T109	TEST 3312 3326	Eosinophil Abs
T110	TEST 3327 3329	Ct
T111	TEST 3336 3342	*****)
T112	TEST 3353 3358	x10E9
T113	TEST 3364 3376	Basophil Abs
T114	TEST 3377 3382	Count
T115	TEST 3404 3423	/L   CANCER ANTIGEN
T116	TEST 3435 3447	Result Value
T117	TEST 3461 3467	Cancer
T118	TEST 3468 3475	Antigen
T119	TEST 3498 3499	U
T120	TEST 3505 3514	BILIRUBIN
T121	TEST 3516 3534	TOTAL       Result
T122	TEST 3545 3550	Range
T123	TEST 3554 3563	Bilirubin
T124	TEST 3565 3570	Total
T125	TEST 3586 3591	mg/dL
T126	TEST 3594 3604	CREATININE
T127	TEST 3606 3611	SERUM
T128	TEST 3634 3639	Value
T129	TEST 3640 3643	Ref
T130	TEST 3644 3649	Range
T131	TEST 3653 3663	Creatinine
T132	TEST 3682 3695	mg/dL    eGFR
T133	TEST 3699 3719	non-African American
T134	TEST 3738 3742	eGFR
T135	TEST 3746 3753	African
T136	TEST 3754 3758	Amer
T137	TEST 3776 3811	ASPARTATE TRANSAMINASE       Result
T138	TEST 3812 3817	Value
T139	TEST 3822 3827	Range
T140	TEST 3831 3853	Aspartate transaminase
T141	TEST 3866 3905	U/L   ALANINE TRANSAMINASE       Result
T142	TEST 3906 3911	Value
T143	TEST 3927 3947	Alanine transaminase
T144	TEST 3960 3986	U/L   ALKALINE PHOSPHATASE
T145	TEST 4019 4039	Alkaline Phosphatase
T146	TEST 4052 4062	U/L     CA
T147	TEST 4093 4111	Preoperative value
T148	TEST 4132 4161	The following imaging studies
T149	TEST 4195 4227	Ct Abdomen /pelvis With Contrast
T150	TEST 4244 4246	CT
T151	TEST 4247 4275	ABDOMEN/PELVIS WITH CONTRAST
T152	TREATMENT 4329 4338	resection
T153	PROBLEM 4343 4350	panc ca
T154	TEST 4381 4394	Comparison CT
T155	TEST 4481 4524	contiguous 1.25-mm collimation axial images
T156	TEST 4572 4602	Coronal and sagittal reformats
T157	TEST 4724 4737	this CT study
T158	TREATMENT 4761 4795	DLP (mGy-cm) radiation dose values
T159	TEST 4843 4863	Chest/Abdomen/Pelvis
T160	TEST 4882 4889	CTDIvol
T161	TEST 4898 4901	DLP
T162	TEST 5014 5016	CT
T163	TEST 5021 5062	the volume Computed Tomography Dose Index
T164	TEST 5232 5266	the CT scanner acquisition factors
T165	TREATMENT 5450 5464	radiation dose
T166	TEST 5529 5547	Biomedical Imaging
T167	TEST 5593 5616	Computed Tomography (CT
T168	TEST 5766 5780	chest findings
T169	PROBLEM 5818 5834	periportal edema
T170	PROBLEM 5897 5931	associated mild biliary dilatation
T171	PROBLEM 5978 5996	tumor infiltration
T172	PROBLEM 6048 6082	Small pneumobilia in the left lobe
T173	TREATMENT 6116 6135	hepaticojejunostomy
T174	PROBLEM 6167 6208	a 14 mm hypodense lesion in segment March
T175	PROBLEM 6231 6272	New 5 mm hypodense lesion in segment 8/4A
T176	PROBLEM 6304 6322	metastatic disease
T177	PROBLEM 6324 6353	Other hypodense liver lesions
T178	TREATMENT 6478 6495	Whipple procedure
T179	PROBLEM 6507 6554	moderate dilatation of the main pancreatic duct
T180	TEST 6590 6600	prior exam
T181	TREATMENT 6709 6726	Whipple procedure
T182	PROBLEM 6763 6802	Enhancing mass in the endometrial canal
T183	PROBLEM 6838 6862	an intracavitary fibroid
T184	TEST 6883 6900	pelvic ultrasound
T185	PROBLEM 6912 6922	malignancy
T186	PROBLEM 6925 6940	Lymphadenopathy
T187	PROBLEM 6942 6982	Multiple reactive mesenteric lymph nodes
T188	PROBLEM 6995 7002	Ascites
T189	PROBLEM 7004 7017	Small ascites
T190	PROBLEM 7028 7049	small amount of fluid
T191	PROBLEM 7054 7092	stranding around the central mesentery
T192	PROBLEM 7106 7124	suspicious lesions
T193	PROBLEM 7197 7241	a 14 mm hypodense lesion in segment March 14
T194	PROBLEM 7246 7287	new 5 mm hypodense lesion in segment 8/4A
T195	PROBLEM 7303 7331	worsening metastatic disease
T196	PROBLEM 7362 7378	periportal edema
T197	PROBLEM 7439 7473	associated mild biliary dilatation
T198	PROBLEM 7520 7538	tumor infiltration
T199	PROBLEM 7593 7632	Enhancing mass in the endometrial canal
T200	PROBLEM 7668 7692	an intracavitary fibroid
T201	TEST 7713 7730	pelvic ultrasound
T202	PROBLEM 7742 7752	malignancy
T203	TEST 7778 7800	Ct Chest With Contrast
T204	TEST 7817 7819	CT
T205	TREATMENT 7897 7906	resection
T206	PROBLEM 7911 7928	pancreatic cancer
T207	PROBLEM 7934 7944	recurrence
T208	TEST 7969 7985	chest radiograph
T209	TEST 7998 8000	CT
T210	TEST 8019 8025	PET/CT
T211	TEST 8064 8109	Serial 1.25 mm axial images through the chest
T212	TREATMENT 8152 8172	intravenous contrast
T213	TEST 8275 8288	this CT study
T214	TREATMENT 8312 8346	DLP (mGy-cm) radiation dose values
T215	TEST 8394 8414	Chest/Abdomen/Pelvis
T216	TEST 8433 8440	CTDIvol
T217	TEST 8449 8452	DLP
T218	TEST 8565 8567	CT
T219	TEST 8572 8613	the volume Computed Tomography Dose Index
T220	TEST 8783 8817	the CT scanner acquisition factors
T221	TREATMENT 9001 9015	radiation dose
T222	TEST 9080 9098	Biomedical Imaging
T223	TEST 9144 9167	Computed Tomography (CT
T224	PROBLEM 9236 9273	Bilateral nonspecific thyroid nodules
T225	PROBLEM 9297 9347	an 8 mm hypodense nodule in the right thyroid lobe
T226	PROBLEM 9350 9395	Scattered lower lobe subsegmental atelectasis
T227	PROBLEM 9421 9434	consolidation
T228	PROBLEM 9438 9454	pleural effusion
T229	PROBLEM 9456 9509	Unchanged calcified granuloma in the right upper lobe
T230	PROBLEM 9511 9542	Few scattered pulmonary nodules
T231	PROBLEM 9653 9668	lymphadenopathy
T232	PROBLEM 9670 9723	Scattered calcified mediastinal and hilar lymph nodes
T233	PROBLEM 9756 9783	old 
 granulomatous disease
T234	PROBLEM 9822 9845	significant abnormality
T235	TREATMENT 9847 9879	Right chest wall Port-A-Cath tip
T236	PROBLEM 9990 10013	suspicious bone lesions
T237	PROBLEM 10030 10077	Mild degenerative changes of the thoracic spine
T238	TEST 10129 10154	evaluation of the abdomen
T239	PROBLEM 10186 10222	Few scattered tiny pulmonary nodules
T240	TEST 10296 10323	clinical oncologic protocol
T241	PROBLEM 10380 10446	Borderline resectable/locally advanced adenocarcinoma the pancreas
T242	TREATMENT 10452 10476	neoadjuvant chemotherapy
T243	TREATMENT 10489 10498	resection
T244	PROBLEM 10523 10541	disease recurrence
T245	TEST 10591 10610	her imaging studies
T246	PROBLEM 10612 10623	The lesions
T247	TEST 10681 10697	repeat her scans
T248	TEST 10738 10759	a confirmatory biopsy
T249	TREATMENT 10887 10897	management
T250	Symptom 158 178	abdominal discomfort
A1	IsPresentOnFirstCancerDiagnosis T250 yes
A2	IsCausedByDiagnosedCancer T250 yes
A3	ChronicVal T250 non-chronic
A4	ContinuityVal T250 new
T251	Symptom 180 188	bloating
A5	IsPresentOnFirstCancerDiagnosis T251 yes
A6	IsCausedByDiagnosedCancer T251 yes
A7	ChronicVal T251 non-chronic
A8	ContinuityVal T251 new
T252	Symptom 204 212	jaundice
A9	IsPresentOnFirstCancerDiagnosis T252 yes
A10	IsCausedByDiagnosedCancer T252 yes
A11	ChronicVal T252 non-chronic
A12	ContinuityVal T252 new
T253	Datetime 144 152	February
R1	HappensAtOnDuring Arg1:T253 Arg2:T250	
R2	HappensAtOnDuring Arg1:T253 Arg2:T251	
R3	HappensAtOnDuring Arg1:T253 Arg2:T252	
T254	ProcedureName 217 228	metal stent
A13	IntentVal T254 others
A14	TreatmentTypeVal T254 others
A15	TreatmentCategory T254 Others
R4	TestOrProcedureConductedForProblem Test:T254 Prob:T250	
R5	TestOrProcedureConductedForProblem Test:T254 Prob:T251	
R6	TestOrProcedureConductedForProblem Test:T254 Prob:T252	
T255	Datetime 243 249	May 29
R7	HappensAtOnDuring Arg1:T255 Arg2:T254	
T256	Radiology 304 311	CT scan
A16	IntentVal T256 diagnosis
T257	Radiology 406 412	PET/CT
A17	IntentVal T257 staging
T258	Radiology 484 508	ultrasound of the pelvis
A18	IntentVal T258 diagnosis
T259	Radiology 633 636	EUS
A19	IntentVal T259 diagnosis
T260	RadPathResult 336 340	mass
A20	RadPathResultVal T260 InitialCancerDiagnosis
T261	RadPathResult 445 449	mass
A21	RadPathResultVal T261 InitialCancerDiagnosis
T262	RadPathResult 890 915	peritoneal carcinomatosis
A22	RadPathResultVal T262 InitialCancerDiagnosis
A23	NegationModalityVal T262 uncertain_in_present
T263	Metastasis 890 915	peritoneal carcinomatosis
A24	NegationModalityVal T263 uncertain_in_present
A25	EpisodeDescription T263 FirstOccurrence
T264	Radiology 820 845	pancreas protocol CT scan
A26	IntentVal T264 staging
T265	Site 348 368	head of the pancreas
T266	RadPathResult 388 392	mass
A27	RadPathResultVal T266 Others
T267	RadPathResult 540 547	fibroid
A28	RadPathResultVal T267 Others
T268	RadPathResult 580 601	thickened endometrium
A29	RadPathResultVal T268 Others
T269	RadPathResult 615 621	masses
A30	RadPathResultVal T269 Others
T270	RadPathResult 662 672	encasement
A31	RadPathResultVal T270 InitialCancerDiagnosis
T271	RadPathResult 699 707	invasion
A32	RadPathResultVal T271 InitialCancerDiagnosis
T272	Site 680 694	hepatic artery
T273	Site 717 728	portal vein
T274	Site 555 575	fundus of the uterus
T275	Site 457 465	pancreas
T276	Site 607 614	adnexal
T277	Site 380 387	adrenal
R8	SiteOf Arg1:T265 Arg2:T260	
R9	SiteOf Arg1:T277 Arg2:T266	
T278	Size 375 379	2 cm
R10	SizeOf Arg1:T278 Arg2:T266	
T279	Size 533 539	3.2 cm
R11	SizeOf Arg1:T279 Arg2:T267	
R12	SiteOf Arg1:T275 Arg2:T261	
T280	RadPathResult 470 478	PET avid
A33	RadPathResultVal T280 InitialCancerDiagnosis
R13	ResultOfTest Desc:T261 Test:T257	
R14	ResultOfTest Desc:T280 Test:T257	
R15	ResultOfTest Desc:T260 Test:T256	
R16	ResultOfTest Desc:T266 Test:T256	
R17	ResultOfTest Desc:T267 Test:T258	
R18	ResultOfTest Desc:T268 Test:T258	
R19	SiteOf Arg1:T274 Arg2:T267	
T281	Datetime 416 420	June
R20	HappensAtOnDuring Arg1:T255 Arg2:T256	
R21	HappensAtOnDuring Arg1:T281 Arg2:T257	
T282	Datetime 517 524	June 05
R22	HappensAtOnDuring Arg1:T282 Arg2:T258	
T283	Datetime 645 651	May 29
R23	SiteOf Arg1:T276 Arg2:T269	
A34	NegationModalityVal T269 negated
R24	ResultOfTest Desc:T269 Test:T258	
R25	SiteOf Arg1:T272 Arg2:T270	
R26	SiteOf Arg1:T273 Arg2:T271	
T284	LocalInvasion 662 672	encasement
A35	EpisodeDescription T284 FirstOccurrence
T285	LocalInvasion 699 707	invasion
A36	EpisodeDescription T285 FirstOccurrence
R27	TestOrProcedureReveals Test:T259 Desc:T284	
R28	TestOrProcedureReveals Test:T259 Desc:T285	
R29	HappensAtOnDuring Arg1:T283 Arg2:T259	
R30	ResultOfTest Desc:T270 Test:T259	
R31	ResultOfTest Desc:T271 Test:T259	
T286	ProcedureName 731 734	FNA
A37	IntentVal T286 diagnosis
T287	Site 742 750	pancreas
R32	SiteOf Arg1:T287 Arg2:T286	
T288	Histology 760 774	adenocarcinoma
R33	TestOrProcedureReveals Test:T286 Desc:T288	
R34	HappensAtOnDuring Arg1:T283 Arg2:T286	
R35	TestOrProcedureReveals Test:T264 Prob:T263	
R36	ResultOfTest Desc:T262 Test:T264	
T289	ProcedureName 934 945	laparoscopy
A38	IntentVal T289 staging
T290	ClinicalCondition 999 1006	ascites
A39	ChronicVal T290 non-chronic
T291	RadPathResult 1046 1054	negative
A40	RadPathResultVal T291 NoDisease
T292	Pathology 1032 1040	washings
A41	IntentVal T292 staging
R37	ResultOfTest Desc:T291 Test:T292	
R38	TestOrProcedureReveals Test:T289 Desc:T290	
T293	RadPathResult 1065 1071	lesion
A42	RadPathResultVal T293 NoDisease
T294	Site 1079 1084	liver
T295	Pathology 1089 1097	biopsied
R39	ResultOfTest Desc:T293 Test:T295	
R40	SiteOf Arg1:T294 Arg2:T293	
T296	RadPathResult 1131 1135	cyst
A43	RadPathResultVal T296 NoDisease
R41	ResultOfTest Desc:T296 Test:T295	
T297	ProcedureName 1150 1161	laparoscopy
A44	IntentVal T297 staging
T298	Symptom 1177 1197	pleuritic chest pain
A45	IsPresentOnFirstCancerDiagnosis T298 no
A46	IsCausedByDiagnosedCancer T298 no
A47	ChronicVal T298 non-chronic
A48	ContinuityVal T298 new
T299	Symptom 1207 1226	shortness of breath
A49	IsPresentOnFirstCancerDiagnosis T299 no
A50	IsCausedByDiagnosedCancer T299 no
A51	ChronicVal T299 non-chronic
A52	ContinuityVal T299 new
R42	ConditionOrTreatmentCausesProblem Treatment:T297 Prob:T298	
R43	ConditionOrTreatmentCausesProblem Treatment:T297 Prob:T299	
T34	ClinicalCondition 1253 1255	PE
A53	NegationModalityVal T34 negated
T300	Radiology 1282 1289	CT scan
A54	IntentVal T300 others
R44	TestOrProcedureReveals Test:T300 Desc:T34	
R45	TestOrProcedureConductedForProblem Test:T300 Prob:T298	
R46	TestOrProcedureConductedForProblem Test:T300 Prob:T299	
T301	RadPathResult 1343 1373	interlobular septal thickening
A55	RadPathResultVal T301 Others
T302	RadPathResult 1380 1402	ground glass opacities
A56	RadPathResultVal T302 Others
R47	ResultOfTest Desc:T301 Test:T300	
R48	ResultOfTest Desc:T302 Test:T300	
T303	MedicationRegimen 1445 1464	modified FOLFIRINOX
A57	TreatmentContinuityVal T303 started
A58	TreatmentTypeVal T303 neoadjuvant
A59	TreatmentIntentVal T303 curative
T304	Cycles 1480 1482	12
R49	TreatmentDesc Therapy:T304 Desc:T303	
T305	ProcedureName 1534 1552	surgical resection
A60	NegationModalityVal T305 hypothetical_in_future
A61	IntentVal T305 treatment-curative
A62	TreatmentTypeVal T305 local
T306	Datetime 1557 1565	March 22
T307	ProcedureName 1583 1712	pylorus-preserving pancreatectomy with open cholecystectomy and portal vein and hepatic artery resection and interposition graft.
A63	IntentVal T307 treatment-curative
A64	TreatmentTypeVal T307 local
A65	IsTumorRemaining T307 no
T308	Pathology 1713 1731	Surgical pathology
A66	IntentVal T308 TreatmentAssessment
T309	RadPathResult 1750 1769;1791 1822	residual tumor mass 51-90% of tumor cells destroyed
A67	RadPathResultVal T309 TreatmentResponse
T310	Size 1743 1749	1.7 cm
A68	EpisodeDescription T310 FirstOccurrence
R50	SizeOf Arg1:T310 Arg2:T309	
R51	ResultOfTest Desc:T309 Test:T308	
T311	MarginStatus 1824 1831	Margins
A69	MarginVal T311 MoreThan2mm(Neg)
R52	ProcedureDesc Procedure:T307 Desc:T311	
T312	LymphNodeInvolvement 1870 1881	lymph nodes
A70	NegationModalityVal T312 negated
A71	EpisodeDescription T312 FirstOccurrence
R53	TestOrProcedureReveals Test:T305 Desc:T312	
R54	TestOrProcedureReveals Test:T308 Desc:T312	
T313	Symptom 2033 2053	abdominal discomfort
A72	IsPresentOnFirstCancerDiagnosis T313 no
A73	IsCausedByDiagnosedCancer T313 no
A74	ContinuityVal T313 new
R55	ConditionOrTreatmentCausesProblem Treatment:T307 Prob:T313	
T314	Symptom 2102 2115	good appetite
A75	NegationModalityVal T314 negated
T315	Symptom 2137 2152	bowel movements
A76	NegationModalityVal T315 negated
T316	Symptom 2161 2175	lost 15 pounds
A77	NegationModalityVal T316 affirmed
A78	IsPresentOnFirstCancerDiagnosis T316 no
A79	IsCausedByDiagnosedCancer T316 no
A80	ChronicVal T316 non-chronic
R56	ConditionOrTreatmentCausesProblem Treatment:T307 Prob:T316	
T317	SectionSkip 2198 2761	Objective:    Vitals: BP 148/79 | Pulse 84 | Temp(Src) 36.7 C (98.1 F) (Oral) | Resp 16 | Ht 173 cm (5' 8.11") | Wt 79.561 kg (175 lb 6.4 oz) | BMI 26.58 kg/m2 | SpO2 100% | LMP 10/08/1998   In general, she appears comfortable.  HEENT no icterus  Nodes no clinical adenopathy  Neck without thyromegaly  Lungs clear to A and P  Heart RR without murmur or gallop  Abd somewhat distended. Right side is tender to palpation. No fluid wave.  GU not done  Skin without rash or petechiae  Extrem without edema and pedal pulses are full  Neuro without gross focal deficit
A81	SectionSkipType T317 physical_exam
T318	SectionSkip 2765 3911;3914 4092	Results for orders placed in visit on 04/26/15   COMPLETE BLOOD COUNT WITH 5-PART DIFFERENTIAL       Result Value Ref Range    WBC Count 5.7  3.4 - 10 x10E9/L    RBC Count 3.57 (*****) 4.0 - 5.2 x10E12/L    Hemoglobin 9.5 (*****) 12.0 - 15.5 g/dL    Hematocrit 30.5 (*****) 36 - 46 %    MCV 85  80 - 100 fL    MCH 26.6  26 - 34 pg    MCHC 31.1  31 - 36 g/dL    Platelet Count 171  140 - 450 x10E9/L    Neutrophil Absolute Count 3.19  1.8 - 6.8 x10E9/L    Lymphocyte Abs Cnt 1.60  1.0 - 3.4 x10E9/L    Monocyte Abs Count 0.44  0.2 - 0.8 x10E9/L    Eosinophil Abs Ct 0.48 (*****) 0.0 - 0.4 x10E9/L    Basophil Abs Count 0.03  0.0 - 0.1 x10E9/L   CANCER ANTIGEN 19-9       Result Value Ref Range    Cancer Antigen 19-9 2250 (*****) <36 U/mL   BILIRUBIN, TOTAL       Result Value Ref Range    Bilirubin, Total 0.4  0.2 - 1.3 mg/dL   CREATININE, SERUM / PLASMA       Result Value Ref Range    Creatinine 0.86  0.52 - 1.06 mg/dL    eGFR if non-African American 72  >60 mL/min    eGFR if African Amer 83  >60 mL/min   ASPARTATE TRANSAMINASE       Result Value Ref Range    Aspartate transaminase 23  17 - 42 U/L   ALANINE TRANSAMINASE       Result Value Ref Range    Alanine transaminase 17  11 - 50 U/L   ALKALINE PHOSPHATASE       Result Value Ref Range    Alkaline Phosphatase 89  31 - 95 U/L     CA 19-9 dated April 26 was 2250.
A82	SectionSkipType T318 laboratory
T319	SectionSkip 4093 4129	Preoperative value in January was 44
A83	SectionSkipType T319 laboratory
T320	SectionSkip 4132 5864;5867 7825;7828 9759;9762 10356	The following imaging studies are reviewed and interpreted:    Ct Abdomen /pelvis With Contrast    04/26/2015   CT ABDOMEN/PELVIS WITH CONTRAST  *****/*****/***** 8:37 AM  CLINICAL HISTORY: Pt s/p resection for panc ca; r/o recurrence  COMPARISON:  Comparison CT from 01/12/2015.  TECHNIQUE: Following the administration of 150 cc of Omnipaque 350, contiguous 1.25-mm collimation axial images were obtained through the abdomen and pelvis.  Coronal and sagittal reformats were also obtained.  RADIATION DOSE INDICATORS:  ***** *****-***** received 1 exposure event(s) (excluding scout) during this CT study. The CTDIvol (mGy) and DLP (mGy-cm) radiation dose values for each event are:  Event: 1;  anatomic area: Chest/Abdomen/Pelvis;  phantom: body;  CTDIvol: 11.1;  DLP: 699.1  The following accession numbers are related to this dose report [*****]: *****  The dose indicators for CT are the volume Computed Tomography Dose Index (CTDIvol) and the Dose Length Product (DLP), and are measured in units of mGy and mGy-cm, respectively. These indicators are not patient dose, but values generated from the CT scanner acquisition factors.  Individual patient doses calculated from these values will depend on patient size and can substantially underestimate or overestimate the actual dose. For additional information on radiation dose, safety, and protection in the UCSF Department of Radiology and Biomedical Imaging, please refer to one of our FAQ leaflets on "Computed Tomography (CT)" or go to *****://*****.*****.*****.*****/*****/*****.   FINDINGS:  Visualized lung bases:  Please see separately dictated report from same day for chest findings.   Liver:    Interval development of periportal edema involving the lateral segment of the left hepatic lobe with associated mild biliary dilatation. This may be postsurgical in nature. However, tumor infiltration is not entirely excluded. Attention on follow-up.  Small pneumobilia in the left lobe is noted. Patient is status post hepaticojejunostomy.  Interval increase in size of a 14 mm hypodense lesion in segment March 14 (previously 9 mm). New 5 mm hypodense lesion in segment 8/4A is noted and is suspicious for metastatic disease. Other hypodense liver lesions are not significantly changed.  Gallbladder:  Surgically absent.   Spleen:  Unremarkable  Pancreas:  Patient is status post Whipple procedure . There is moderate dilatation of the main pancreatic duct, stable to slightly increased from prior exam.  Adrenal Glands:  Unremarkable  Kidneys:  Unremarkable  Vasculature:  Unremarkable  GI Tract:  Status post Whipple procedure. Otherwise, unremarkable.  Pelvis:  Enhancing mass in the endometrial canal is noted. This may be secondary to an intracavitary fibroid. However, recommend pelvic ultrasound to exclude malignancy.  Lymphadenopathy: Multiple reactive mesenteric lymph nodes are noted.  Ascites: Small ascites. There is small amount of fluid and stranding around the central mesentery.  Bones:  No suspicious lesions     04/26/2015   IMPRESSION: //ALERT//   1.Interval increase in size of a 14 mm hypodense lesion in segment March 14 and new 5 mm hypodense lesion in segment 8/4A, suggestive of worsening metastatic disease.   2. Interval development of periportal edema involving the lateral segment of the left hepatic lobe with associated mild biliary dilatation. This may be postsurgical in nature. However, tumor infiltration is not entirely excluded. Attention on follow-up.  3. Enhancing mass in the endometrial canal is noted. This may be secondary to an intracavitary fibroid. However, recommend pelvic ultrasound to exclude malignancy.  END OF IMPRESSION:     Ct Chest With Contrast    04/26/2015   CT CHEST WITH CONTRAST   *****/*****/***** 8:37 AM  CLINICAL HISTORY:  Pt s/p resection for pancreatic cancer; r/o recurrence  COMPARISON: 03/22/2015 chest radiograph; 01/12/2015 CT chest; 06/15/2014 PET/CT from an outside hospital.  TECHNIQUE: Serial 1.25 mm axial images through the chest were obtained after the administration of intravenous contrast.  RADIATION DOSE INDICATORS:  ***** *****-***** received 1 exposure event(s) (excluding scout) during this CT study. The CTDIvol (mGy) and DLP (mGy-cm) radiation dose values for each event are:  Event: 1;  anatomic area: Chest/Abdomen/Pelvis;  phantom: body;  CTDIvol: 11.1;  DLP: 699.1  The following accession numbers are related to this dose report [*****]: *****  The dose indicators for CT are the volume Computed Tomography Dose Index (CTDIvol) and the Dose Length Product (DLP), and are measured in units of mGy and mGy-cm, respectively. These indicators are not patient dose, but values generated from the CT scanner acquisition factors.  Individual patient doses calculated from these values will depend on patient size and can substantially underestimate or overestimate the actual dose. For additional information on radiation dose, safety, and protection in the UCSF Department of Radiology and Biomedical Imaging, please refer to one of our FAQ leaflets on "Computed Tomography (CT)" or go to *****://*****.*****.*****.*****/*****/*****.  FINDINGS:  Bilateral nonspecific thyroid nodules again noted, including an 8 mm hypodense nodule in the right thyroid lobe.  Scattered lower lobe subsegmental atelectasis is new from previous. No consolidation or pleural effusion. Unchanged calcified granuloma in the right upper lobe. Few scattered pulmonary nodules measuring up to 3 mm in the subpleural aspect of the right upper lobe are unchanged, series 301 image 58.  No lymphadenopathy. Scattered calcified mediastinal and hilar lymph nodes are unchanged and suggestive of old granulomatous disease.  The heart and great vessels show no significant abnormality. Right chest wall Port-A-Cath tip extends through the tricuspid valve into the right ventricle, previously terminating in the right atrium.  No suspicious bone lesions are identified. Mild degenerative changes of the thoracic spine.  Please see a separately reported examination for evaluation of the abdomen.     04/26/2015   IMPRESSION:  Few scattered tiny pulmonary nodules measuring up to 3 mm, unchanged since 09/16/2014. Continued followup per clinical oncologic protocol recommended.  END OF IMPRESSION:
A84	SectionSkipType T320 radiology_report
T321	ClinicalCondition 10419 10447	adenocarcinoma the pancreas,
A85	ChronicVal T321 non-chronic
T322	LocalInvasion 10391 10418	resectable/locally advanced
A86	NegationModalityVal T322 negated
A87	EpisodeDescription T322 FirstOccurrence
R57	TumorDesc TumorDetails:T321 Desc:T322	
T323	TreatmentType 10452 10476	neoadjuvant chemotherapy
A88	TreatmentContinuityVal T323 finished
A89	TreatmentTypeVal T323 neoadjuvant
A90	TreatmentIntentVal T323 curative
T324	TreatmentType 10489 10498	resection
A91	IntentVal T324 treatment-curative
A92	TreatmentContinuityVal T324 finished
A93	TreatmentTypeVal T324 local
A94	TreatmentIntentVal T324 curative
T325	DiseaseState 10523 10541	disease recurrence
A95	NegationModalityVal T325 uncertain_in_present
A96	DiseaseStateVal T325 progression-recurrence
T326	Radiology 10595 10610	imaging studies
A97	IntentVal T326 TreatmentAssessment
R58	TestOrProcedureReveals Test:T326 Desc:T325	
T327	RadPathResult 10616 10623	lesions
A98	NegationModalityVal T327 uncertain_in_present
A99	RadPathResultVal T327 Progression
R59	ResultOfTest Desc:T327 Test:T326	
T328	Size 10628 10637	too small
R60	SizeOf Arg1:T328 Arg2:T327	
T329	Duration 10701 10710	2 months.
T330	Radiology 10692 10697	scans
A100	IntentVal T330 TreatmentAssessment
A101	NegationModalityVal T330 planned_in_future
R61	HappensAtOnDuring Arg1:T329 Arg2:T330	
T331	ProcedureName 10740 10759	confirmatory biopsy
A102	NegationModalityVal T331 hypothetical_in_future
T332	PerformanceStatus 10552 10553	0
A103	PerformanceStatusType T332 ECOG
T333	Age 39 41	63
T334	PatientCharacteristics 51 67	African American
R62	TestOrProcedureReveals Test:T256 Desc:T278	
R63	TestOrProcedureReveals Test:T258 Desc:T279	
R64	HappensAtOnDuring Arg1:T307 Arg2:T306	
R65	TestOrProcedureReveals Test:T308 Desc:T310	
R66	HappensAtOnDuring Arg1:T306 Arg2:T308	
R67	TestOrProcedureReveals Test:T326 Desc:T328	
T335	hpi_end 2186 2194	surgery.
T336	ap_start 10362 10372	Assessment
T337	ap_end 10753 10760	biopsy.
